A price cap on insulin from one of the three major manufacturers took effect on New Year's Day, giving more Americans with diabetes more affordable treatments. As of Jan. 1, 2024, Sanofi cut the ...

Heavyweight insulin-maker Novo Nordisk said Tuesday that it will lower list prices for some of its insulin products by up to 75 percent by the end of the year, following in the footsteps of Eli ...

Laura Barron-Lopez: So, what took effect this month was that Sanofi followed suit with Eli Lilly and Novo Nordisk to implement this cap on insulin co-pays at $35 that took effect January 1. Now ...

Over 30 million Americans have diabetes, and more than 7 million of them require daily insulin. But the cost of the drug has risen considerably in the last decade. Though U.S. lawmakers are ...

March 1 (Reuters) - Eli Lilly and Co (LLY.N), opens new tab on Wednesday said it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning from ...

The axing of the insulin cap provision in the Senate’s budget reconciliation deal would leave millions of people scrambling to cover exorbitant out-of-pocket prices for the diabetes medication.

The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted ...

ST. PAUL, Minn. — Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable ...

For patients with diabetes, insulin is a life-saving medicine and an essential component of diabetes management, yet in the past decade alone, the out-of-pocket costs for insulin have doubled in the ...

Millions of people with diabetes need insulin to survive. For years, many of them have been forced to pay exorbitant prices for a product that's inexpensive to make. Now, the federal government is ...

Despite promises by pharmaceutical companies to limit insulin price hikes, the life-saving drug remains out of reach for many patients with diabetes — with fatal, or near-fatal, results.